1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Revenio Group Oyj
  6. News
  7. Summary
    REG1V   FI0009010912

REVENIO GROUP OYJ

(REG1V)
  Report
Real-time Estimate Cboe Europe  -  05/23 08:00:14 am EDT
46.14 EUR   -0.52%
02:31aREVENIO GROUP CORPORATION : Managers' Transactions – Ari Isomäki
AQ
05/20REVENIO GROUP CORPORATION : Managers' Transactions – Heli Huopaniemi
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Arne Boye Nielsen
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Revenio Group Corporation: Notice pursuant to chapter 9, section 5 of the securities market act

10/14/2020 | 02:46pm EDT

Revenio Group Corporation, Stock Exchange Release, October 14, 2020 at 21.45

Notice pursuant to chapter 9, section 5 of the securities market act

Revenio Group Corporation has October 13, 2020 received a notification of change in holdings in accordance with Chapter 9, Section 5 of the Securities Markets Act that The Capital Group Companies Inc's share of the total number of shares and voting rights in Revenio Group Corporation has decreased to less than five per cent.

The Capital Group Companies Inc now holds 1.288.756 shares in Revenio Group Corporation, which is 4.8399 per cent of the company's shares and voting rights.

The total number of Revenio Group Corporation's shares recorded in the trade register is 26.627.557.

Revenio Group Corporation

For further information, please contact:

CFO Robin Pulkkinen, tel.  +358 50 505 9932
robin.pulkkinen@revenio.fi
www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Ltd

Financial Supervisory Authority

Main media

www.revenio.fi

Revenio Group in brief

Revenio, a health technology group operating in the international markets, is one of the global leaders in ophthalmic appliances. Revenio Group's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the Icare brand and retinal imaging devices. The main tool for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).

The Revenio Group consists of Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.

The common denominators of Revenio's business operations include patient-oriented screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The aim is to improve the quality of life through health technology solutions which enable more effective diagnostics. Revenio Group's focus is on the early detection of glaucoma, diabetic retinopathy and macular degeneration, and the monitoring of these during the treatment process. Revenio Research concentrates on the commercialization of systems supporting the diagnosis of and treatment planning for skin cancer and asthma.

In 2019, Revenio Group's net sales totalled EUR 49.5 million, with its net operating profit standing at 25.5 %. Revenio Group Corporation is listed on Nasdaq Helsinki.

https://news.cision.com/revenio-group-oyj/r/revenio-group-corporation--notice-pursuant-to-chapter-9--section-5-of-the-securities-market-act,c3216215

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about REVENIO GROUP OYJ
02:31aREVENIO GROUP CORPORATION : Managers' Transactions – Ari Isomäki
AQ
05/20REVENIO GROUP CORPORATION : Managers' Transactions – Heli Huopaniemi
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Arne Boye Nielsen
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Ann-Christine Sundell
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Bill Östman
AQ
05/11REVENIO GROUP CORPORATION : Transfer of the Company's own shares
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Riad Sherif
AQ
05/11REVENIO GROUP CORPORATION : Managers' Transactions – Pekka Tammela
AQ
04/28TRANSCRIPT : Revenio Group Oyj, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28Revenio Group Corporation's Vice Chairman has been elected
AQ
More news
Financials
Sales 2022 93,8 M 99,0 M 99,0 M
Net income 2022 22,1 M 23,3 M 23,3 M
Net cash 2022 11,5 M 12,1 M 12,1 M
P/E ratio 2022 55,2x
Yield 2022 0,83%
Capitalization 1 232 M 1 300 M 1 300 M
EV / Sales 2022 13,0x
EV / Sales 2023 10,8x
Nbr of Employees 184
Free-Float 80,0%
Chart REVENIO GROUP OYJ
Duration : Period :
Revenio Group Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REVENIO GROUP OYJ
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 46,38 €
Average target price 49,13 €
Spread / Average Target 5,92%
EPS Revisions
Managers and Directors
Jouni Erik Toijala President & Chief Executive Officer
Robin Allan Pulkkinen Chief Financial Officer
Arne Boye Nielsen Chairman
Mika Salkola Director-Research & Development
Ari Isomäki Operations Director
Sector and Competitors
1st jan.Capi. (M$)
REVENIO GROUP OYJ-16.51%1 300
SARTORIUS AG-36.47%23 746
BIOTAGE AB (PUBL)-26.98%1 267
VAREX IMAGING CORPORATION-30.24%877
CELLAVISION AB (PUBL)5.78%824
908 DEVICES INC.-44.53%451